211 related articles for article (PubMed ID: 27769766)
1. Prescribing of cyproterone acetate/ethinylestradiol in UK general practice: a retrospective descriptive study using The Health Improvement Network.
Cea Soriano L; Asiimwe A; García Rodriguez LA
Contraception; 2017 Mar; 95(3):299-305. PubMed ID: 27769766
[TBL] [Abstract][Full Text] [Related]
2. Thrombotic risk minimization for Diane-35 and generics.
Bezemer ID; Smits E; Penning-van Beest FJA; Asiimwe A; Herings RMC
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1411-1417. PubMed ID: 28952198
[TBL] [Abstract][Full Text] [Related]
3. Differences in the use of combined oral contraceptives amongst women with and without acne.
Seaman HE; de Vries CS; Farmer RD
Hum Reprod; 2003 Mar; 18(3):515-21. PubMed ID: 12615817
[TBL] [Abstract][Full Text] [Related]
4. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.
Bitzer J; Römer T; Lopes da Silva Filho A
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):172-182. PubMed ID: 28447864
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database.
Seaman HE; de Vries CS; Farmer RD
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):427-36. PubMed ID: 15269926
[TBL] [Abstract][Full Text] [Related]
6. [The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type].
Gollnick H; Albring M; Brill K
Ann Endocrinol (Paris); 1999 Sep; 60(3):157-66. PubMed ID: 10520404
[TBL] [Abstract][Full Text] [Related]
7. Prescription Appropriateness of Cyproterone Acetate/Ethinylestradiol in Primary Care: A Population-Based Study in Italy.
Lapi F; Simonetti M; Cricelli I; Cricelli C; Cassano N; Vena GA
Clin Drug Investig; 2017 Aug; 37(8):755-762. PubMed ID: 28434141
[TBL] [Abstract][Full Text] [Related]
8. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.
Ruan X; Kubba A; Aguilar A; Mueck AO
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):183-190. PubMed ID: 28463030
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
Falsetti L; Galbignani E
Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
Vartiainen M; de Gezelle H; Broekmeulen CJ
Eur J Contracept Reprod Health Care; 2001 Mar; 6(1):46-53. PubMed ID: 11334476
[TBL] [Abstract][Full Text] [Related]
11. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy.
Franks S; Layton A; Glasier A
Hum Reprod; 2008 Feb; 23(2):231-2. PubMed ID: 18083746
[TBL] [Abstract][Full Text] [Related]
12. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
Seaman HE; de Vries CS; Farmer RD
Hum Reprod; 2003 Mar; 18(3):522-6. PubMed ID: 12615818
[TBL] [Abstract][Full Text] [Related]
13. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
[TBL] [Abstract][Full Text] [Related]
15. Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK.
Cea-Soriano L; Wallander MA; García Rodríguez LA
J Fam Plann Reprod Health Care; 2016 Oct; 42(4):247-254. PubMed ID: 27098200
[TBL] [Abstract][Full Text] [Related]
16. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects.
van Wayjen RG; van den Ende A
Exp Clin Endocrinol Diabetes; 1995; 103(4):241-51. PubMed ID: 7584530
[TBL] [Abstract][Full Text] [Related]
17. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
[TBL] [Abstract][Full Text] [Related]
18. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens.
Kelekci KH; Kelekci S; Yengel I; Gul S; Yilmaz B
J Dermatolog Treat; 2012 Jun; 23(3):177-83. PubMed ID: 21254871
[TBL] [Abstract][Full Text] [Related]
19. Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy.
Penning-van Beest FJA; Bezemer ID; Smits E; García Rodríguez LA; Cea Soriano L; Lapi F; Simonetti M; Asiimwe A; Herings RMC
Contraception; 2020 Oct; 102(4):243-245. PubMed ID: 32470466
[TBL] [Abstract][Full Text] [Related]
20. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
